Pharmafile Logo
Pharmafocus logo
Advanced Search

Yescarta

Showing 11 posts of 11 posts found.

FDA building

FDA approves Kite’s Yescarta therapy for follicular lymphoma

March 9, 2021
Manufacturing and Production FDA, Kite, Yescarta

The FDA has granted accelerated approval to Kite’s Yescarta treatment, a medicine for adult patients with relapsed or refractory follicular …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

August 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Air pollution, CAR-T therapy, HIV, Kymriah, Medicare, Novartis, Yescarta, Zolgensma

Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the …

News
scotland

Gilead’s CAR-T therapy Yescarta rejected for NHS use in Scotland

February 12, 2019
Manufacturing and Production, Sales and Marketing CAR-T, Cancer, Gilead, NHS, Scotland, Yescarta, kite pharma

It’s bad news for Scottish patients living with aggressive forms of non-Hodgkin lymphoma (NHL) as it emerges that the Scottish …

News
gilead-sciences

NICE give go-ahead to Gilead’s Yescarta for adults with lymphoma

December 7, 2018
Medical Communications Cancer, Cost, Gilead, NHS, NICE, Yescarta, access

The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma. Gilead’s treatment will …

News
gilead-sciences

Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma

December 3, 2018
Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma

Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …

News
gilead_hq_at_stockley_park_london_2

NHS England appoves Gilead’s CAR T therapy Yescarta

October 5, 2018
Medical Communications Gilead, NHS, NICE, UK, Yescarta

Gilead’s CAR T therapy Yescarta is set to be made available on the NHS in England for adults with aggressive …

News
european_commission_web

Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies

August 28, 2018
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …

News
novartis_window

Novartis becomes first to gain second CAR T indication

May 2, 2018
Research and Development, Sales and Marketing Gilead, Kymriah, Novartis, Yescarta, biotech, drugs, pharma, pharmaceutical

Novartis has announced that its CAR T treatment, Kymriah, has successfully been given a second indication for the treatment of …

News
gilead-sciences

Gilead aims to claim edge with Pfizer CAR-T combo

January 18, 2018
Medical Communications, Research and Development Gilead, Kite, Yescarta, biotech, drugs, pharma, pharmaceutical

Although those in pharma often dislike any references to drugs competing with each other for market as in a ‘race’, …

News
_97604447_kymriah-product-shot-8

CAR-T is bringing true precision to the fight against cancer

November 1, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Gilead, Kymriah, Novartis, Yescarta

Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment …

Feature
gilead-sciences

Gilead gets FDA nod for revolutionary blood cancer treatment

October 19, 2017
Sales and Marketing CAR-T, Gilead, Yescarta, biotech, drugs, pharma, pharmaceutical

Only weeks after Gilead announced the completion of Kite, it got the news it was hoping for with the FDA’s …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024